Anti-Inflammatory and Anti-asthmatic Agents

Anti-Inflammatory and Anti-asthmatic Agents

Download Presentation
(108) |   (0) |   (0)
Views: 107 | Added: 03-10-2012
Rate Presentation: 0 0
Objectives. List two mast cell stabilizers.Describe and diagram the antigen/antibody reaction on mast cellsExplain which antibody is elevated in allergic asthma.List three mediators that are released with inflammation.Explain the effects of chemical mediators such as histamine and leukotrienes o
Anti-Inflammatory and Anti-asthmatic Agents

An Image/Link below is provided (as is) to

Download Policy: Content on the Website is provided to you AS IS for your information and personal use only and may not be sold or licensed nor shared on other sites. SlideServe reserves the right to change this policy at anytime. While downloading, If for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

1. Anti-Inflammatory and Anti-asthmatic Agents MODULE F

2. Objectives List two mast cell stabilizers. Describe and diagram the antigen/antibody reaction on mast cells Explain which antibody is elevated in allergic asthma. List three mediators that are released with inflammation. Explain the effects of chemical mediators such as histamine and leukotrienes on airway epithelium.

3. Objectives Given signs and symptoms, differentiate between the early and late phase of an inflammatory response. Describe how cromolyn sodium and nedocromil are anti-inflammatory agents. State the generic and trade names, modes of action, adverse reactions, routes of administration, dosages, and adverse reactions for cromolyn sodium and nedocromil sodium. State the origin of corticosteroid secretion. Describe why corticosteroids are now considered first line drugs in the treatment of asthma. Describe the pathway for the release and control of corticosteroids in the body.

4. Objectives Define HPA insufficiency. Differentiate between systemic and inhaled corticosteroids. List three actions of steroids on inflammation. Describe the process of weaning a patient from steroids. List four side effects or adverse reactions of steroid administration. State the trade and generic names of the inhaled steroids discussed in class.

5. Objectives Describe how a RCP can decrease the incidence of oral fungal infections when administering aerosolized steroids. List three leukotrienes inhibitors discussed in class. State two side effects of leukotrienes. State how leukotrienes are administered. Describe the cellular mechanism for leukotriene production. State three medication types that are used for upper-airway congestion. State the IgE inhibitor used to treat asthma.

6. Anti-Inflammatory Drugs Non-Steroidal Anti-inflammatory Mast Cell Stabilizers or anti-asthmatics Leukotriene Antagonists (anti-leukotrienes) Adrenocorticosteroid Anti-inflammatory Corticosteroids or Steroids

8. Mechanism of Inflammation Mast Cells, eosinophils, macrophages, basophils are found in submucosa. The cells contain granules that are storehouses of the chemical mediators of lung inflammation. Antigen-Antibody reactions causes the influx of Ca+2 into the cells and release of mediators. IgE primary antibody

9. Mechanism of Inflammation Mediator Release Bronchospasm Vasodilation resulting in mucosal edema Increased vascular permeability Increased mucus gland secretion

10. Mediators of Inflammation Histamine Platelet Activating Factor Eosinophil Chemotactic Factor of Anaphylaxis (ECF-A) Neutrophil Chemotactic Factor of Anaphylaxis (NCF-A) Leukotrienes (formerly known as slow-reacting substance of anaphylaxis ? SRS-A) Prostaglandins

11. Explanation of Mast Cell rupture (Degranulation) Figure 7-1, p. 132 Mast cells are found throughout the body and their sensitization explains the watery eyes, runny nose, etc. that accompanies an allergic reaction.

12. Phases of Inflammatory Response in Asthma Early phase - Immediate Late phase ? 6 to 8 hours after exposure

13. Early Phase Local vasodilation Increased vascular permeability Redness Bronchoconstriction Wheezing Coughing Dyspnea Hypoxemia

14. Late Phase Effect of WBC (lymphocyte) and other mediators Hypersecretion of mucus and mucosal swelling Traffic Jam Breakdown of Mast Cell releases Arachidonic Acid Production of leukotrienes Prostaglandin

16. Goal of Therapy Stop Mast Cell from degranulating Prophylactic Anti-asthmatics Stop specific inflammatory processes Corticosteroids Broad spectrum response Leukotriene Inhibitors Antihistamines Prostaglandin Inhibitors

17. Mast Cell Stabilizers Prevent Ca+2 influx into the cell, thereby preventing mediator release. cromolyn sodium Intal, Nasalcrom nedocromil sodium Tilade Ketotifen (Experimental) Zaditen These medications do not operate through the C?AMP system and do not stimulate b or a receptor sites Best used in limited populations and mild asthma

18. Indications for Mast Cell Stabilizers Prophylactic management of Asthma. Pre-treatment for expected exposure. Prevention of exercise induced asthma Allergic rhinitis Do not use to treat an asthmatic attack

19. cromolyn sodium (1973) Small Volume Nebulizer Concentration: 1% Supplied in a 2 mL ampule (unit dose) containing 20 mg (20 mg/2 mL). Give one ampule QID; may need to add additional diluent (2 mL may nebulize too quickly). MDI: 0.8 mg/inhalation 2 inhalations QID Ophthalmic and Nasal solutions available

20. Hazards/Adverse Reactions Generally well tolerated Nasal congestion Throat irritation Hoarseness Dry mouth Cough Feeling of chest tightness Wheezing/Sneezing/Epistaxis Give b2 agonist prior to administering Cromolyn

21. nedocromil sodium (1992) Tilade MDI: 1.75 mg/inhalation 2 inhalations QID Side Effects similar to cromolyn

22. Adrenocorticosteroids Secreted from the adrenal cortex. Epinephrine secreted from adrenal medulla. Multiple functions of medication. Anti-inflammatory. Orally, parenterally, aerosol. First line drugs in the management of asthma. Reliever and controller medication. Given to control allergies.

23. Adrenal Gland

24. HPA Axis Hypothalamic Pituitary Adrenal Axis Low blood levels of steroids. Hypothalamus is stimulated. Sends impulse to Anterior Pituitary Gland which stimulates Corticotropin Releasing Factor (CRF). This stimulates the formation of Adrenocorticotropin hormone (ACTH ). ACTH in bloodstream stimulates Adrenal Cortex to produce and release Corticosteroids. Increases blood levels of corticosteroids.

26. HPA Axis Diurnal or Circadian Rhythm Levels are highest around 8:00 a.m. Off-shift workers. Giving a patient steroids can suppress the body?s HPA axis (Body stops producing steroids). If you stop the added steroids abruptly, the patient will experience HPA insufficiency and death can occur.

27. HPA Insufficiency Once adrenal suppression has occurred, the patient must be weaned slowly from systemic steroids. This will allow for recovery of the body?s own secretion. HPA insufficiency begins 1 day after use of systemic steroid administration.

28. Prevention of HPA Insufficiency Low dose steroid for 5 days or less. Take steroids in the morning when natural levels are high. High dose tapered regimen lasting 5-6 days. Alternate day therapy.

30. Cushing's Syndrome Increased secretion of corticosteroids caused by a tumor of the adrenal glands Cushingoid appearance Central obesity Moon face Buffalo hump

31. Aerosolized Steroids Advantage is that aerosolized steroids do not increase the blood levels of steroids Does not cause HPA insufficiency Less side effects Goal is to try to gain control of asthma with the aerosolized steroids May take 4-8 weeks for maximum improvement

32. Oral vs. Aerosol Corticosteroids

33. Common Inhaled Steroids

34. Adverse Reactions of Aerosolized Steroids Fungal Infections may occur after aerosol Rinse mouth and use spacer Throat irritation, hoarseness, dry mouth and coughing have occurred HPA insufficiency may occur during transfer from systemic to aerosol steroids Severe asthma may occur following withdrawal of oral/IV steroids

35. Adverse Reactions/Precautions Aerosolized steroids may not be adequate to control asthma during periods of stress and systemic administration may be necessary

36. Leukotriene Modifiers Anti-Leukotrienes Leukotriene Antagonists Leukotriene Inhibitors

37. Leukotriene Inhibitors Indications Prophylactic treatment of asthma ?Controllers? Not to be used to treat an asthma attack zileuton Zyflo zafirlukast Accolate montelukast Singulair

39. Leukotriene Inhibitors zileuton (Zyflo) 12 years of age or older Works well in aspirin-sensitive asthmatics 600 mg orally QID Elevate liver enzymes Interaction with Warfarin Seldane Theophylline Propanolol 5 - Lipoxygenase inhibitor

40. Leukotriene Inhibitors zafirlukast (Accolate) 12 years of age or older 10 or 20 mg orally BID Elevates liver enzymes Interactions Warfarin Theophylline Blocks the leukotriene receptor site (leukotriene receptor antagonist)

41. Leukotriene Inhibitors montelukast (Singular) Daily dosing 4 mg packet of granules (6 to 23 months ) 4 mg chewable tablet or 4 mg packet of granules (2 to 5 years of age) 5 mg chewable tablet (child) 10 mg tablet (adult) Side effects: headache, influenza, abdominal pain Blocks the leukotriene receptor site (Leukotriene receptor antagonist)

42. Disadvantage of Anti-leukotrienes Inhibit one mediator pathway Asthma involves multiple mediators 50 ? 70% of patients respond to the medication Trial & Error

43. Upper Airway Congestion Allergic Rhinitis Antihistamine Prevents release of histamine. Significant side effects Newer generation are more ?forgiving? Intranasal Medications Mast Cell Stabilizers (Nasalcrom) Nasal Steroids Decongestants a-adrenergic agents Vasoconstriction Table 7-14 (page 140)

45. IGE Inhibitors omalizumab (Xolair)

46. Dosing

Other Related Presentations

Copyright © 2014 SlideServe. All rights reserved | Powered By DigitalOfficePro